HTX-001
Asset
Antisense oligonucleotide targeting WISPER long noncoding RNA to reduce cardiac fibrosis.
- Stage
- Phase 1
- Modality
- Oligonucleotide
- Target
- WISPER
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Nonobstructive hypertrophic cardiomyopathy
Phase 1, Recruiting, NCT07867288, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.